title: Palatability of angiotensin II antagonists among nephropathic children.
abstract: BACKGROUND
  * Among children, medication palatability is crucial for adherence to therapeutic regimen. * Several studies have measured the palatability of antimicrobial suspensions in paediatric patients by means of a visual analogue scale palatability score.
  
  
  CONCLUSIONS
  * This is the first analysis comparing the taste and smell acceptability of angiotensin II receptor blockers among paediatric patients with kidney disease. * From the perspective of the child with kidney disease, the taste of pulverized candesartan is significantly superior to that of pulverized irbesartan, losartan, telmisartan or valsartan.
  
  
  OBJECTIVE
  Angiotensin II receptor blockers are widely prescribed in kidney disease. Among children, medication palatability is crucial for adherence.
  
  
  METHODS
  Taste and smell acceptability of five angiotensin II receptor blockers were compared among 21 nephropathic children using a visual analogue scale palatability score.
  
  
  RESULTS
  The score assigned to pulverized tablets of candesartan cilexetil was significantly higher than that assigned to pulverized tablets of irbesartan, losartan, telmisartan and valsartan.
  
  
  CONCLUSIONS
  From the perspective of the nephropathic child, the taste of pulverized candesartan cilexetil is superior to that of irbesartan, losartan, telmisartan or valsartan.
authors.affiliation: Ospedale San Giovanni Bellinzona and Ospedale della Beata Vergine, Mendrisio, Switzerland.
authors.forename: Chiara M
authors.initials: CM
authors.lastname: Meier
authors.forename: Giacomo D
authors.initials: GD
authors.lastname: Simonetti
authors.forename: Silvia
authors.initials: S
authors.lastname: Ghiglia
authors.forename: Emilio
authors.initials: E
authors.lastname: Fossali
authors.forename: Patrizia
authors.initials: P
authors.lastname: Salice
authors.forename: Costanzo
authors.initials: C
authors.lastname: Limoni
authors.forename: Mario G
authors.initials: MG
authors.lastname: Bianchetti
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D001565:Benzoates / Q000627:therapeutic use; D001713:Biphenyl Compounds / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D005260:Female; D006801:Humans; D000077405:Irbesartan; D007674:Kidney Diseases / Q000188:drug therapy*; D019808:Losartan / Q000627:therapeutic use; D008297:Male; D010349:Patient Compliance; D017060:Patient Satisfaction; D012903:Smell; D013649:Taste; D000077333:Telmisartan; D013777:Tetrazoles / Q000627:therapeutic use; D014633:Valine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000068756:Valsartan
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D000959:Antihypertensive Agents; D001562:Benzimidazoles; D001565:Benzoates; D001713:Biphenyl Compounds; D013777:Tetrazoles; D000068756:Valsartan; D014633:Valine; D000077405:Irbesartan; D019808:Losartan; C077793:candesartan cilexetil; D000077333:Telmisartan